Skip to content
Mohammed Salhab

Mohammed Salhab, MD, is a board certified medical oncologist and hematologist in Golden and Thornton, CO. He treats all cancers in adults, including breast, colorectal, lung, urological, leukemia, lymphoma and multiple myeloma.



Special Interests


Clinical research for lung cancer, small cell and non small cell lung cancer.

Education


Awards & Recognition


2015: Best senior resident

Board Certification


2015: Internal Medicine
2018: Hematology
2018: Medical Oncology

Professional Memberships


American Society of Clinical Oncology
American Society of Hematology
Society for Immunotherapy of Cancer

Publications


Salhab M, Migdady Y, Donahue M, Xiong Y, Dresser K, Walsh W, Chen BJ, Liebmann J. Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. J Immunother Cancer. 2018 May 29;6(1):42 16. Zhu X,
 
Salhab M, Donahue M and Walsh W. Pembrolizumab for platinum refractory small cell carcinoma of the prostate, case report. Hematol Med Oncol, 2018
 
Salhab M, Tomaszewicz K, Meng X, Mathew C et all. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in Appendiceal mucinous neoplasms. Human pathology, 2018
 
Epperla, N., Maddocks, K. J., Salhab, M., Chavez, J. C., Reddy, N., Karmali, R., Umyarova, E., Bachanova, V., Costa, C., Glenn, M., Calzada, O., Xavier, A. C., Zhou, Z., Hossain, N. M., Hernandez-Ilizaliturri, F. J., Al-Mansour, Z., Barta, S. K., Chhabra, S., Lansigan, F., Mehta, A., Jaglal, M. V., Evans, A., Flowers, C. R., Cohen, J. B., Fenske, T. S., Hamadani, M. and Costa, L. J. (2017), C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits”and outcomes with subsequent therapy. Cancer.
 
Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C, Muba-rak S, Salhab M, Jiang Y, Granwehr B, Adachi JA, Raad I. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries. Cancer. 2012 Sep; 118 (18): 4627-4633